HBK Investments L P Takes Position in The Cooper Companies, Inc. $COO

HBK Investments L P acquired a new stake in shares of The Cooper Companies, Inc. (NASDAQ:COO) during the second quarter, HoldingsChannel.com reports. The institutional investor acquired 441,651 shares of the medical device company’s stock, valued at approximately $31,666,000.

Other institutional investors have also added to or reduced their stakes in the company. Avalon Trust Co purchased a new position in Cooper Companies during the 2nd quarter valued at about $25,000. Root Financial Partners LLC increased its position in shares of Cooper Companies by 104.5% during the fourth quarter. Root Financial Partners LLC now owns 317 shares of the medical device company’s stock valued at $26,000 after buying an additional 162 shares during the period. SJS Investment Consulting Inc. lifted its holdings in shares of Cooper Companies by 107.5% in the first quarter. SJS Investment Consulting Inc. now owns 361 shares of the medical device company’s stock worth $26,000 after buying an additional 187 shares in the last quarter. Elevation Wealth Partners LLC lifted its holdings in shares of Cooper Companies by 1,136.4% in the second quarter. Elevation Wealth Partners LLC now owns 408 shares of the medical device company’s stock worth $29,000 after buying an additional 375 shares in the last quarter. Finally, Continuum Advisory LLC bought a new position in shares of Cooper Companies in the second quarter valued at approximately $30,000. Hedge funds and other institutional investors own 24.39% of the company’s stock.

Cooper Companies Price Performance

Shares of COO traded up $1.34 during trading hours on Wednesday, reaching $54.61. 5,314,057 shares of the company’s stock traded hands, compared to its average volume of 2,517,650. The stock has a market cap of $10.38 billion, a PE ratio of 18.64, a price-to-earnings-growth ratio of 2.21 and a beta of 0.82. The company has a current ratio of 1.22, a quick ratio of 0.73 and a debt-to-equity ratio of 0.23. The firm’s 50 day simple moving average is $70.88 and its 200-day simple moving average is $69.19. The Cooper Companies, Inc. has a 12 month low of $51.01 and a 12 month high of $89.83.

Cooper Companies (NASDAQ:COO) last posted its quarterly earnings data on Wednesday, September 9th. The medical device company reported $1.15 earnings per share for the quarter, topping the consensus estimate of $1.12 by $0.03. The company had revenue of $1.07 billion for the quarter, compared to analysts’ expectations of $1.10 billion. Cooper Companies had a net margin of 13.46% and a return on equity of 10.90%. Cooper Companies’s revenue for the quarter was up .5% compared to the same quarter last year. During the same period in the prior year, the business earned $0.49 earnings per share. Cooper Companies has set its Q4 2026 guidance at 1.050-1.090 EPS and its FY 2026 guidance at 4.510-4.550 EPS. Equities analysts expect that The Cooper Companies, Inc. will post 4.53 EPS for the current year.

Cooper Companies announced that its Board of Directors has initiated a stock buyback program on Wednesday, September 9th that permits the company to buyback $3.00 billion in shares. This buyback authorization permits the medical device company to reacquire up to 22.7% of its shares through open market purchases. Shares buyback programs are usually an indication that the company’s leadership believes its stock is undervalued.

More Cooper Companies News

Here are the key news stories impacting Cooper Companies this week:

• Positive Sentiment: Three directors made substantial purchases after the selloff: Paul Keel bought 4,701 shares, Lawrence Kurzius bought 10,000 shares and Walter Rosebrough Jr. purchased 10,000 shares across two transactions. The combined buying of approximately $1.33 million may signal that insiders view COO’s valuation as attractive after the decline. Insider purchase report
• Positive Sentiment: The company’s previously announced $3 billion share-repurchase authorization, potentially covering up to 22.7% of outstanding shares, could provide support if management follows through. Third-quarter adjusted EPS of $1.15 also exceeded the $1.12 consensus estimate. Cooper Companies financial information
• Negative Sentiment: Revenue was approximately $1.07 billion, below the roughly $1.10 billion analyst expectation. Cooper also reduced its full-year outlook, with adjusted EPS now projected at $4.51–$4.55 and revenue at $4.23–$4.25 billion, reflecting slower contact-lens demand and continuing U.S. channel inventory reductions at CooperVision. Levi and Korsinsky investor notice
• Negative Sentiment: Analyst sentiment has deteriorated: the reported consensus price target was reduced 14.83% to $72.27, while several firms downgraded COO or lowered their ratings following the results. This reinforces investor concerns that the earnings slowdown may persist. Consensus price target report
• Negative Sentiment: Several law firms, including Bragar Eagel & Squire, Levi & Korsinsky and Kirby McInerney, announced investigations into potential securities-law claims involving Cooper Companies. The investigations do not establish wrongdoing, but they add legal, reputational and headline risk while the stock is near its one-year low. Bragar Eagel and Squire investigation

Insiders Place Their Bets

In related news, Director Walter Rosebrough, Jr. purchased 7,000 shares of the business’s stock in a transaction on Friday, September 11th. The stock was acquired at an average price of $54.11 per share, with a total value of $378,770.00. Following the purchase, the director directly owned 17,000 shares in the company, valued at approximately $919,870. This represents a 70.00% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, Director Lawrence Kurzius purchased 10,000 shares of the firm’s stock in a transaction dated Monday, September 14th. The stock was bought at an average cost of $53.91 per share, for a total transaction of $539,100.00. Following the acquisition, the director directly owned 21,099 shares in the company, valued at approximately $1,137,447.09. The trade was a 90.10% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. Insiders purchased a total of 24,701 shares of company stock valued at $1,330,739 in the last quarter. Corporate insiders own 2.08% of the company’s stock.

Wall Street Analysts Forecast Growth

Several brokerages recently commented on COO. JPMorgan Chase & Co. reduced their price objective on shares of Cooper Companies from $71.00 to $58.00 and set a “neutral” rating for the company in a research note on Thursday, September 10th. Zacks Research cut shares of Cooper Companies from a “hold” rating to a “strong sell” rating in a research note on Friday, September 11th. Mizuho set a $75.00 price target on shares of Cooper Companies and gave the company an “outperform” rating in a report on Thursday, September 10th. William Blair lowered shares of Cooper Companies from an “outperform” rating to a “market perform” rating in a research report on Thursday, September 10th. Finally, KeyCorp reaffirmed a “sector weight” rating on shares of Cooper Companies in a report on Friday, June 5th. Five analysts have rated the stock with a Buy rating, eleven have issued a Hold rating and three have assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Hold” and an average price target of $71.47.

About Cooper Companies

Cooper Companies, Inc is a global medical device company headquartered in San Ramon, California. Founded in 1958, the company develops, manufactures and markets products through two primary business segments: CooperVision and CooperSurgical.

CooperVision specializes in contact lenses, including daily disposable, toric, multifocal, multifocal toric, specialty and myopia-management lenses. Its products are designed to address a range of vision-correction needs, including astigmatism, presbyopia and irregular corneas.